🌐 EnglishEN

AI Cure is a research tool showing open data. Not medical advice. Discuss with your doctor. Terms

← Trials
🧪

Superiority Trial Evaluating Digitalized Information Media for Patients With Advanced Sarcomas Receiving Systemic Treatment.

RecruitingNAAges 18 Years - anyAllCentre Oscar Lambret
NCT06211257 on ClinicalTrials.gov ↗
💬

In plain words

What the trial is, and whether it could suit you

ePPS-2202 is a study designed to evaluate the benefits of a dematerialised personalised care plan (PCP) compared to standard information/PCP for patients with advanced sarcomas receiving systemic treatment. Participants will be randomised to an experimental group or a control group. Patients in the experimental group will receive the dematerialised PCP in addition to the standard PCP while patients in the control group will receive the standard PCP alone. All patients will be followed until the end of second-line treatment, the start of a new line of treatment, or until the 24-month follow-up.

Sign in to get the eligibility rules as simple questions to take to your doctor.

Sign in
📋 Eligibility rules (as published)
Inclusion Criteria: * Sarcomas of soft tissues or viscera ; * Inoperable metastatic or locally advanced disease ; * Indication for systemic treatment with pazopanib, trabectedine, eribulin, ifosfamide or dacarbazine monotherapy ; * Patient covered by French social security ; * Written, signed, informed consent ; Exclusion Criteria: * Prior inclusion in ePPS trial for a prior systemic treatment ; * Poor understanding of French ; * Difficulty accessing a computer ; * Pregnant or nursing woman ; * Person deprived of liberty or under guardianship ; * Impossibility of undergoing medical follow-up for geographical, social or psychological reasons.
💊

What it tests

  • Dematerialized Personalized Care Plan (ePCP)
📍

Where

11 sites
Centre Léon Bérard
Lyon, France
CHU Jean Minjoz
Besançon, France
Centre Eugène Marquis
Rennes, France
Centre Paul Strauss
Strasbourg, France
Centre Oscar Lambret
Lille, France
CHU de Poitiers
Poitiers, France
Institut Claudius Regaud
Toulouse, France
Institut de Cancérologie de l'Ouest
Saint-Herblain, France

…and 3 more on ClinicalTrials.gov.

🤝 Taking part is your choice, and you can leave at any time. Only the trial team can confirm you are eligible — always decide together with your own doctor.
🛡️

AI Cure shows public evidence (Open Targets, ClinicalTrials.gov, PubMed, openFDA, DepMap, AlphaFold) with its source, and AI summaries that cite it — not medical advice and not a cure. Treatment decisions belong with your doctor. Research ideas are shared only with approved researchers and labs, who can test them. In an emergency call your local emergency number (112 in India and Europe, 911 in the US). AI Cure Terms of Use · Privacy